BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1640739)

  • 21. Idarubicin, high-dose cytarabine, and etoposide for induction of remission in acute leukemia.
    Mehta J; Powles R; Singhal S; Horton C; Hamblin M; Zomas A; Saso R; Prendiville J; Glynne P; Allford S; Mackay H; Treleaven J
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):18-23. PubMed ID: 8916312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of idarubicin/cytosine arabinoside versus daunorubicin/cytosine arabinoside in the treatment of adults with acute myeloid leukemia.
    Pashko S; Jacobs J; Santorsa J
    Clin Ther; 1991; 13(3):353-60. PubMed ID: 1954636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Acute myeloid leukemia originating from the same leukemia clone after the complete remission of acute lymphoid leukemia].
    Matsuda I; Nakamaki T; Amaya H; Kiyosaki M; Kawakami K; Yamada K; Yokoyama A; Hino K; Tomoyasu S
    Rinsho Ketsueki; 2003 Sep; 44(9):946-51. PubMed ID: 14577315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy.
    Hiddemann W; Martin WR; Sauerland CM; Heinecke A; Büchner T
    Leukemia; 1990 Mar; 4(3):184-8. PubMed ID: 2314117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
    Clavio M; Venturino C; Pierri I; Garrone A; Miglino M; Canepa L; Balleari E; Balocco M; Michelis GL; Ballerini F; Gobbi M
    Ann Hematol; 2004 Nov; 83(11):696-703. PubMed ID: 15322763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
    te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
    Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
    Bishop JF; Matthews JP; Young GA; Bradstock K; Lowenthal RM
    Leuk Lymphoma; 1998 Jan; 28(3-4):315-27. PubMed ID: 9517503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute leukemia in adults: assessment of remission induction with combination chemotherapy by clinical and cell-culture criteria.
    Curtis JE; Cowan DH; Bergsagel DE; Hasselback R; McCulloch EA
    Can Med Assoc J; 1975 Aug; 113(4):289-94. PubMed ID: 1056807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA; Harrington DP; Appelbaum FR; Lazarus HM; Rowe JM; Paietta E; Willman C; Hurd DD; Bennett JM; Blume KG; Head DR; Wiernik PH
    N Engl J Med; 1998 Dec; 339(23):1649-56. PubMed ID: 9834301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group.
    Arlin Z; Case DC; Moore J; Wiernik P; Feldman E; Saletan S; Desai P; Sia L; Cartwright K
    Leukemia; 1990 Mar; 4(3):177-83. PubMed ID: 2179638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Testoni N; Clavio M; Cenacchi A; Gamberi B; Carrara P
    Leukemia; 1994 Nov; 8(11):1842-6. PubMed ID: 7526088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of acute myelocytic leukemia. Daunomycin contrasted with a combination of cytosine arabinoside and 6-thioguanine.
    Poth JL; Johnson PK; George RP; Schrier SL
    Calif Med; 1972 Dec; 117(6):1-11. PubMed ID: 4508367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Consolidation of therapy of acute myeloid leukemia with the AML-BFM 93 protocol in children in the Czech Republic].
    Starý J; Gajdos P; Blazek B; Ptoszková H; Hrstková H; Kopecná L; Tousovská K; Hak J; Procházková D; Cerná Z; Jabali Y; Timr P; Vávra V; Sedlácek P; Smísek P; Hrusák O; Michalová K
    Cas Lek Cesk; 2004; 143(4):257-63. PubMed ID: 15218726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
    Hatoum HA; Mahfouz RA; Otrock ZK; Hudaib AR; Taher AT; Shamseddine AI
    Am J Hematol; 2007 Jan; 82(1):69-72. PubMed ID: 16947317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study.
    Farag SS; Ruppert AS; Mrózek K; Mayer RJ; Stone RM; Carroll AJ; Powell BL; Moore JO; Pettenati MJ; Koduru PR; Stamberg J; Baer MR; Block AW; Vardiman JW; Kolitz JE; Schiffer CA; Larson RA; Bloomfield CD
    J Clin Oncol; 2005 Jan; 23(3):482-93. PubMed ID: 15534356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
    Colla S; Sammarelli G; Crugnola M; Ascani S; Sabbatini E; Bonomini S; Hojden M; Craviotto L; De Celis I; Morandi F; Caramatti C; Rizzoli V; Giuliani N
    Eur J Haematol; 2004 May; 72(5):361-5. PubMed ID: 15059073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.